Kodiak Sciences Inc. (NASDAQ:KOD) Receives $13.00 Consensus Target Price from Brokerages

Kodiak Sciences Inc. (NASDAQ:KOD) has earned a consensus recommendation of “Hold” from the five research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $13.00.

KOD has been the topic of a number of research analyst reports. HC Wainwright increased their price objective on shares of Kodiak Sciences from $3.00 to $5.00 and gave the company a “neutral” rating in a research report on Monday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Kodiak Sciences in a report on Saturday, September 27th. Wall Street Zen raised Kodiak Sciences from a “sell” rating to a “hold” rating in a report on Friday, September 26th. Jefferies Financial Group assumed coverage on Kodiak Sciences in a research report on Monday, September 22nd. They set a “buy” rating and a $15.00 price objective for the company. Finally, Barclays raised Kodiak Sciences from an “underweight” rating to an “equal weight” rating and raised their target price for the stock from $7.00 to $17.00 in a research report on Thursday, September 25th.

Kodiak Sciences Price Performance

Kodiak Sciences stock opened at $15.06 on Friday. Kodiak Sciences has a one year low of $1.92 and a one year high of $19.39. The business’s fifty day moving average is $10.24 and its 200 day moving average is $6.04. The stock has a market capitalization of $795.47 million, a PE ratio of -3.96 and a beta of 2.67.

Kodiak Sciences (NASDAQ:KOD) last posted its earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.02). As a group, sell-side analysts expect that Kodiak Sciences will post -3.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. US Bancorp DE increased its stake in shares of Kodiak Sciences by 131.7% in the 1st quarter. US Bancorp DE now owns 9,282 shares of the company’s stock worth $26,000 after purchasing an additional 5,276 shares in the last quarter. Vontobel Holding Ltd. purchased a new stake in Kodiak Sciences in the first quarter worth about $28,000. Headlands Technologies LLC raised its stake in shares of Kodiak Sciences by 256.4% in the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after buying an additional 5,815 shares during the period. Walleye Capital LLC bought a new position in shares of Kodiak Sciences in the first quarter worth about $49,000. Finally, Vanguard Personalized Indexing Management LLC lifted its position in shares of Kodiak Sciences by 21.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company’s stock valued at $56,000 after buying an additional 2,691 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.